Long-term ibuprofen regimen after brain injury worsens cognition in an...( (Philadelphia PA) -- Researchers at t...)

Long-term ibuprofen regimen after brain injury worsens cognition in animal study

(Philadelphia, PA) -- Researchers at the University of Pennsylvania School of Medicine found that chronic ibuprofen therapy given after brain injury worsens cognitive abilities. These findings in a preliminary, animal-model study have important implications for traumatic brain injury (TBI) patients who are often prescribed such nonsteroidal anti-inflammatory drugs (NSAIDS) as ibuprofen for chronic pain. The findings appear online this month in Experimental Neurology.

Because several studies in animals and humans have shown that long-term use of ibuprofen for inflammation improves outcome for Alzheimer's patients by reducing symptoms and delaying the onset of dementia, the researchers investigated whether ibuprofen improved long-term cognitive outcome in brain-injured animals.

Over four months, rats received ibuprofen in their food proportional to doses given to humans. In the two groups of injured rats (one fed ibuprofen and the other not), there was a significant overall deficit in the animals' ability to find an underwater platform in a Morris water maze, a common test used to assess cognitive ability in animals.

"But to our surprise, we found that the injured rats given ibuprofen were far worse compared to the injured rats that had no treatment at all," says lead author Douglas H. Smith, MD, Director of the Center for Brain Injury and Repair. "Although most untreated injured animals could find the platform, they were much slower to learn its location than non-injured animals. In contrast, almost none of the treated, injured animals could find the platform at all."

However, there were no outward signs of difference in the extent of atrophy in the hippocampus or cortex of treated versus non-treated injured rats. Although ibuprofen treatment did reduce chronic inflammatory changes in the brains of injured animals, that did not seem to have an influence over the extent of damage to the brain regions associated with lear
'"/>

Contact: Karen Kreeger
karen.kreeger@uphs.upenn.edu
215-349-5658
University of Pennsylvania School of Medicine
21-Jul-2006

Page: 1 2
Related medicine news :

1. Long-term treatment with VYVANSE, first prodrug stimulant, demonstrates significant efficacy in ADHD
2. Long-term anti-clotting therapy sweetens stenting outcomes in diabetic patients
3. Long-term aspirin use associated with reduced risk of dying in women
4. Long-term data on safety and effectiveness of antiobesity drugs needed
5. Long-term financial costs associated with prostate cancer treatment
6. Long-term effects of non-alcoholic fatty liver disease
7. Long-term outcomes for prostate cancer show IMRT Curative: 89 percent disease-free 8 years later
8. Long-term abstinence may resolve many of the neurocognitive deficits associated with alcoholism
9. Long-term safety results released for breast cancer drugs
10. Media availability: Long-term survival of heart attack patients with shock
11. Long-term estrogen therapy linked to breast cancer risk

Post Your Comments: